Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 2 of 2 also mention Demis Hassabis, the most common co-covered peer. Across a 123-day span, the pace is roughly 0.1 stories per week. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window.
Last mentioned: Aug 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 2 of 2 also mention Demis Hassabis, the most common co-covered peer. Across a 123-day span, the pace is roughly 0.1 stories per week. The 7.5 average consequence score is above the beat benchmark of 6.1 in the same window. Each story carries 3.5 original sources on average, compared with 3.4 for the broader beat in this window. This profile follows 2 Biotech stories mentioning Google DeepMind across the period from February 18, 2026 to June 20, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 498 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Google DeepMind. Shared-story counts are live from our verified record — not editorial picks.
Nobel laureate John Jumper’s move from Google DeepMind to Anthropic casts uncertainty over the future of AlphaFold, the AI that revolutionized protein structure prediction for drug discovery. Biotech and pharma companies relying on its 200 million predicted structures now watch as Jumper’s expertise may shift to a startup facing legal battles.
Source: english.aawsat.com · cnbc.com
Google DeepMind CEO Demis Hassabis predicts Artificial General Intelligence (AGI) could arrive within five to eight years, ushering in a 'golden era of science' for drug discovery. While the timeline suggests a radical acceleration of biological engineering, Hassabis issued urgent warnings regarding biosecurity risks as AI systems gain autonomous capabilities.
Source: freepressjournal.in · moneycontrol.com
Google DeepMind is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
